Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Convertible Debt: 2020-2024

Historic Convertible Debt for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $93.3 million.

  • Apellis Pharmaceuticals' Convertible Debt rose 0.34% to $93.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $93.5 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $93.3 million for FY2024, which is 0.33% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Convertible Debt is $93.3 million, which was up 0.33% from $93.0 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Convertible Debt ranged from a high of $358.8 million in FY2020 and a low of $92.7 million during FY2022.
  • Moreover, its 3-year median value for Convertible Debt was $93.0 million (2023), whereas its average is $93.0 million.
  • Its Convertible Debt has fluctuated over the past 5 years, first slumped by 50.94% in 2022, then grew by 0.33% in 2024.
  • Apellis Pharmaceuticals' Convertible Debt (Yearly) stood at $358.8 million in 2020, then crashed by 47.32% to $189.0 million in 2021, then plummeted by 50.94% to $92.7 million in 2022, then rose by 0.32% to $93.0 million in 2023, then increased by 0.33% to $93.3 million in 2024.